MHC-I downregulation is correlated with immunotherapy resistance in PDAC, but efficient strategies to increase cell-surface MHC-I are still lacking. This study by Sang, Zhou, Chen, Yu, and colleagues identified inhibition of tumor-intrinsic RIPK2 as a pharmacologic target to block the degradation of MHC-I on tumor cells and improved PDAC responses to anti-PD-1 immunotherapy.

Original languageEnglish
Pages (from-to)208-210
Number of pages3
JournalCancer discovery
Issue number2
StatePublished - 2024


Dive into the research topics of '“RIPping” off Pancreas Cancer’s Blockage of Immune Surveillance'. Together they form a unique fingerprint.

Cite this